Journal
HELLENIC JOURNAL OF CARDIOLOGY
Volume 61, Issue 1, Pages 42-45Publisher
HELLENIC CARDIOLOGICAL SOC
DOI: 10.1016/j.hjc.2020.03.002
Keywords
COVID; Cardiac; Troponin; CRP; Complications
Categories
Funding
- Hellenic Society of Cardiology (Athens, Greece)
- Fundacion Alfonso Martin Escudero (Madrid, Spain)
- ELPEN Pharmaceutical Co. Inc.
- Hellenic Society of Rhythmology
Ask authors/readers for more resources
Objective: Colchicine has been utilized safely in a variety of cardiovascular clinical conditions. Among its potential mechanisms of action is the non-selective inhibition of NLRP3 inflammasome which is thought to be a major pathophysiologic component in the clinical course of patients with COVID-19. GRECCO-19 will be a prospective, randomized, open-labeled, controlled study to assess the effects of colchicine in COVID-19 complications prevention. Methods: Patients with laboratory confirmed SARS-CoV-2 infection (under RT PCR) and clinical picture that involves temperature >37.5 oC and at least two out of the: i. sustained coughing, ii. sustained throat pain, iii. Anosmia and/or ageusia, iv. fatigue/tiredness, v. PaO2<95 mmHg will be included. Patients will be randomised (1:1) in colchicine or control group. Results: Trial results will be disseminated through peer-reviewed publications and conference presentations. Conclusion: GRECCO-19 trial aims to identify whether colchicine may positively intervene in the clinical course of COVID-19. (C) 2020 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available